 Oxidative stress is an important factor in the development of type 2 diabetes, T2D. Unfortunately, most clinical studies have failed to provide sufficient evidence regarding the benefits of antioxidants, alexes, and treating this disease. This could be due to the fact that inappropriate doses of alexes are being administered, leading to their failure as a treatment option. Furthermore, the role of oxidative stress in the pathophysiology of T2D is described, along with a summary of the evidence for the failure of alexes in the management of diabetes. Additionally, the possibility that glycemic control might be adversely affected by excess alexes is also considered, based on the role of ROS in insulin signaling. It is suggested that alex therapy should be given in a personalized manner according to the need, which is the presence and severity of oxidative stress. With the development of gold standard biomarkers for oxidative stress, optimization of alex therapy may be achieved to maximize the therapeutic potential of these agents. This article was authored by Lytle, Argie, Frankel, and Tovitt, Rosenzweig. We are article.tv. Links in the description below.